A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

Tun Jen Hsiao, Lawrence Shih Hsin Wu, Shih Yi Huang, Eugene Lin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (-11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P <0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P <0.001) for subjects with the CC genotype. On the contrary, sibutramine had no significant effect on percent body fat loss or on weight loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ gene may contribute to weight reduction and fat loss in response to sibutramine therapy in Taiwanese obese patients.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalClinical Pharmacology: Advances and Applications
Volume2
Issue number1
Publication statusPublished - 2010

Fingerprint

sibutramine
Adiponectin
Body Composition
Weight Loss
Obesity
Adipose Tissue
Genes
Single Nucleotide Polymorphism
Therapeutics
Fats
Placebos
Collagen
Genotype

Keywords

  • Body fat
  • Obesity
  • Sibutramine
  • Single nucleotide polymorphisms
  • Weight loss

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity. / Hsiao, Tun Jen; Wu, Lawrence Shih Hsin; Huang, Shih Yi; Lin, Eugene.

In: Clinical Pharmacology: Advances and Applications, Vol. 2, No. 1, 2010, p. 105-110.

Research output: Contribution to journalArticle

@article{b632e359e76f47859764448e3f3c56b9,
title = "A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity",
abstract = "In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (-11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5{\%}; P <0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P <0.001) for subjects with the CC genotype. On the contrary, sibutramine had no significant effect on percent body fat loss or on weight loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ gene may contribute to weight reduction and fat loss in response to sibutramine therapy in Taiwanese obese patients.",
keywords = "Body fat, Obesity, Sibutramine, Single nucleotide polymorphisms, Weight loss",
author = "Hsiao, {Tun Jen} and Wu, {Lawrence Shih Hsin} and Huang, {Shih Yi} and Eugene Lin",
year = "2010",
language = "English",
volume = "2",
pages = "105--110",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

AU - Hsiao, Tun Jen

AU - Wu, Lawrence Shih Hsin

AU - Huang, Shih Yi

AU - Lin, Eugene

PY - 2010

Y1 - 2010

N2 - In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (-11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P <0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P <0.001) for subjects with the CC genotype. On the contrary, sibutramine had no significant effect on percent body fat loss or on weight loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ gene may contribute to weight reduction and fat loss in response to sibutramine therapy in Taiwanese obese patients.

AB - In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (-11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P <0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P <0.001) for subjects with the CC genotype. On the contrary, sibutramine had no significant effect on percent body fat loss or on weight loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ gene may contribute to weight reduction and fat loss in response to sibutramine therapy in Taiwanese obese patients.

KW - Body fat

KW - Obesity

KW - Sibutramine

KW - Single nucleotide polymorphisms

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=77955477553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955477553&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77955477553

VL - 2

SP - 105

EP - 110

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

IS - 1

ER -